{"id":"NCT01646073","sponsor":"AbbVie (prior sponsor, Abbott)","briefTitle":"Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Adalimumab (HumiraÂ®) in Chinese Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-08","primaryCompletion":"2013-12","completion":"2013-12","firstPosted":"2012-07-20","resultsPosted":"2015-01-19","lastUpdate":"2015-01-19"},"enrollment":425,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Plaque Psoriasis"],"interventions":[{"type":"BIOLOGICAL","name":"Adalimumab","otherNames":["ABT-D2E7","Humira"]},{"type":"BIOLOGICAL","name":"placebo","otherNames":[]}],"arms":[{"label":"Adalimumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A study to evaluate the safety and efficacy of adalimumab in Chinese subjects with moderate to severe plaque psoriasis.","primaryOutcome":{"measure":"Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response at Week 12","timeFrame":"Week 12","effectByArm":[{"arm":"Placebo","deltaMin":11.5,"sd":null},{"arm":"Adalimumab Eow","deltaMin":77.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":16,"countries":["China"]},"refs":{"pmids":[],"seeAlso":["http://www.rxabbvie.com"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":87},"commonTop":["UPPER RESPIRATORY TRACT INFECTION","NASOPHARYNGITIS","OROPHARYNGEAL PAIN","COUGH"]}}